GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
View original at globenewswire.comGILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases Foster City, Calif…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Gamgertamig is a potential first-in-class and best-in-class T cell engager in autoimmune diseases
60% confidenceGamgertamig is expected to enter registrational studies as early as 2027
60% confidenceGamgertamig is designed to enable rapid and deep plasma cell and B cell depletion following a limited subcutaneously administered treatment course with the potential to induce durable disease control in severe antibody-mediated orphan diseases
60% confidenceGilead operates in more than 35 countries worldwide
60% confidenceLakefront's year-end 2026 cash balance is expected to be approximately €2 billion
60% confidenceFollowing the transaction, Lakefront will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities
60% confidenceThe acquisition builds on Gilead's long-term strategy to shift treatment paradigms from chronic disease management toward the potential for durable immune reset
60% confidence